Chemomab Therapeutics Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CMMB Nasdaq 2836 www.chemomab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Chemomab Therapeutics Ltd.

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - May 14th, 2026 6:00 am
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update - Mar 19th, 2026 6:00 am
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 17th, 2026 6:00 am
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology - Dec 2nd, 2025 6:00 am
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit - Nov 24th, 2025 6:00 am
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 20th, 2025 6:00 am
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis - Nov 6th, 2025 6:00 am
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - Oct 23rd, 2025 8:27 am
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Oct 22nd, 2025 8:18 am
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - Oct 17th, 2025 9:52 am
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - Oct 16th, 2025 9:14 am
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - Oct 15th, 2025 9:31 am
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Oct 14th, 2025 9:24 am
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - Oct 10th, 2025 10:21 am
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Oct 10th, 2025 8:27 am
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - Oct 8th, 2025 9:18 am
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Oct 8th, 2025 9:15 am
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - Aug 21st, 2025 6:00 am
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 14th, 2025 6:00 am
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25 - Jun 30th, 2025 6:00 am